These findings underscore the importance of exploring novel therapeutic combinations to overcome the resistance of MSS CRC to Anti-PD-1/PD-L1 therapy and to modify the tumor microenvironment to enhance treatment outcomes. The gene discussed is CD274; the disease is neoplasm.